BACKGROUND: @entity4184 (Entocort) is effective for the treatment of @entity4143 . AIM: To assess the long-term outcome of @entity1 after induction of clinical remission by @entity4184 treatment. METHODS: Fifty-one @entity1 with chronic @entity294 and histologically proven @entity4143 were enrolled in randomized, placebo-controlled crossover trial using @entity4184 9 mg daily for 6 weeks. @entity1 in clinical remission after either initial or crossover @entity4184 treatment were followed using standardized questionnaires. Clinical relapse was defined as five or more loose stools/day for at least 4 consecutive days. RESULTS: A total of 33 @entity1 achieved clinical remission (85% per-protocol). During a median follow-up of 16 months, clinical relapse occurred in 20 @entity1 (61%), after a median time of 2 weeks (range: 1-104, mean: 10 weeks). @entity1 age <60 years was identified as a significant risk factor for clinical relapse (OR = 7.4, P = 0.048). @entity4184 was used for treatment of clinical relapse in 80% of @entity1 achieving clinical response in all of them. CONCLUSIONS: @entity4184 is effective in the treatment of @entity4143 . Clinical relapses may occur in a considerable number of @entity1 , particularly in those <60 years. Treatment of clinical relapse with @entity4184 appears to be an effective option.

Long-term follow-up of XXXX after induction of clinical remission with @entity4184 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'Patient'] @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhoea'] @entity4143 :: ('MESH:D046729', 'Disease') :: ['collagenous colitis'] @entity4184 :: ('MESH:D019819', 'Chemical') :: ['Budesonide', 'budesonide']
@entity4143 :: (MESH:D046729,Disease) :: ['collagenous colitis']
